Table I.
Demographic characteristics of pancreas islet cell transplant recipients. Despite similar demographic profiles and the fact that NMSC incidence rates between the 2 groups were nonsignificant, the average age at the first NMSC occurrence was significantly lower in the allogeneic group
| Allogeneic transplant recipients, n | Autologous transplant recipients, n | P value | |
|---|---|---|---|
| Total number of participants | 6 | 6 | |
| Sex (%) | |||
| Male | 2 (33.3) | 1 (16.7) | 1.00 |
| Female | 4 (66.7) | 5 (83.3) | |
| Age at first transplantation (years) | |||
| Mean (SD) | 49.8 (5.8) | 47.5 (10.6) | .64 |
| Median (range) | 48.5 (45-60) | 47.5 (33-61) | |
| Race | |||
| White (%) | 6 (100) | 4 (66.7) | .45 |
| Nonwhite (%) | 0 | 2 (33.3) | |
| History of nonmelanoma skin cancer prior to transplant (%) | 0 | 0 | |
| Melanoma developed after first islet cell transplant (%) | 0 | 0 | |
| Nonmelanoma skin cancer developed after first transplant (%) | 5 (83.3) | 2 (33.3) | .24 |
| Incidences of cutaneous squamous cell carcinoma during follow-up period (n) | 7 | 1 | |
| Incidences of basal cell carcinoma during follow-up period (n) | 1 | 1 | |
| Incidence rates of NMSC | 0.106 | 0.026 | .12 |
| Developed Merkel cell carcinoma or any other skin cancer besides melanoma and NMSC after transplant (%) | 0 | 0 | |
| On long-term antirejection immunosuppression (mycophenolate mofetil and tacrolimus) for >1 year (%) | 6 (100) | 0 | |
| Age at the first skin cancer occurrence after transplant (years) | |||
| Mean (SD) | 55.8 (5.5) | 70 (4.2) | .02 |
| Median (range) | 56.0 (47-61) | 70 (67-73) | |
| Years to skin cancer development after transplant (years) | |||
| Mean (SD) | 8.0 (6.5) | 11 (1.4) | .57 |
| Median (range) | 5 (2-15) | 11 (10-12) | |
NMSC, Nonmelanoma skin cancer; SD, standard deviation.